Скрытые возможности профилактики сердечной недостаточности: роль терапии фенофибратом

Статья посвящена анализу доказательных данных, свидетельствующих о возможности дополнительного снижения риска развития сердечной недостаточности (СН) и ее прогрессирования у пациентов с сахарным диабетом 2-го типа (СД2) и дислипидемией за счет применения фенофибрата. Рассматривается актуальность проблемы уменьшения остаточного риска осложнений СН у коморбидных больных СД2. Приводятся результаты как клинических, так и экспериментальных исследований, в которых установлено положительное влияние фенофибрата, являющегося агонистом рецепторов, активируемых пролифераторами пероксисом, альфа (PPARα), на риск развития и прогрессирования СН, обсуждаются возможные механизмы реализации такого эффекта препарата. Приводятся данные об отличиях терапевтического действия фенофибрата от другого представителя фибратов, которые определяют актуальность его применения в клинической практике. 

1. Greene SJ, Xu H, Chiswell K, Felker GM, Lewsey SC, Divanji PH, et al. One-year outcomes in patients hospitalized for heart failure with reduced ejection fraction prescribed quadruple medical therapy at discharge. JAMA Cardiol. 2026;11(3):293–97. https://doi.org/10.1001/jamacardio.2025.5339

2. van Essen BJ, Ceelen DCH, Ouwerkerk W, Teng TK, Tharshana GN, Hew FM, et al. Pharmacologic treatment of heart failure with reduced ejection fraction: An updated systematic review and network meta-analysis. J Am Coll Cardiol. 2025;86(24):2513–26. https://doi.org/10.1016/j.jacc.2025.08.054

3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al.; ESC Scientific Document Group. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39. https://doi.org/10.1093/eurheartj/ehad195

4. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al.; or preserved ejection fraction. N Engl J Med. 2024;391(16):1475– 85. https://doi.org/10.1056/NEJMoa2407107

5. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974;34(1):29–34. https://doi.org/10.1016/0002-9149(74)90089-7

6. Noumegni SR, Kaze AD, Bertoni AG, Fonarow GC, Echouffo-Tcheugui JB. Diabetes, functional status, and mortality in chronic heart failure. Diabetes Care. 2024;47(11):e88–e89. https://doi.org/10.2337/dc24-1586

7. Ferreira JP, Vasques-Novoa F, Ferrao D, Saraiva F, Falcao-Pires I, Neves JS, et al. Fenofibrate and heart failure outcomes in patients with type 2 diabetes: Analysis from ACCORD. Diabetes Care. 2022;45(7):1584–91. https://doi.org/10.2337/dc21-1977

8. Kim JY, Kim NH, Lee J, Kim DH, Kim SG. Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: A propensity-matched cohort study. Eur Heart J Cardiovasc Pharmacother. 2025;11(7):620–29. https://doi.org/10.1093/ehjcvp/pvaf053

9. Hida Y, Imamura T, Kinugawa K. Pemafibrate and cardiac reverse remodeling in patients with systolic heart failure receiving guideline-directed medical therapy. J Cardiol Cases. 2024;31(2):42–45. https://doi.org/10.1016/j.jccase.2024.10.001

10. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al.; PROMINENT Investigators. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923–34. https://doi.org/10.1056/NEJMoa2210645

11. d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, et al.; FIELD Study Investigators. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: Results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014;57(11):2296–303. https://doi.org/10.1007/s00125-014-3344-3

12. Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: A multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521–38. https://doi.org/10.5551/jat.44412

13. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366(9500):1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2

14. Liu M, Lim ST, Song W, Coffman TM, Wang X. Beyond lipids: Fenofibrate in diabetic retinopathy and nephropathy. Trends Pharmacol Sci. 2026;47(3):325–41. https://doi.org/10.1016/j.tips.2025.07.014

15. Liu X, Zhang J, Zhou W, Liu J, Wang Y. Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes. Cell Mol Biol (Noisy-le-grand). 2023;69(2):110–14. https://doi.org/10.14715/cmb/2023.69.2.18

16. Neubauer S. The failing heart – an engine out of fuel. N Engl J Med. 2007;356(11):1140–51. https://doi.org/10.1056/NEJMra063052

17. Li X, Bi X. Integrated control of fatty acid metabolism in heart failure. Metabolites. 2023;13(5):615. https://doi.org/10.3390/metabo13050615

18. Flavell DM, Wootton PT, Myerson SG, World MJ, Pennell DJ, Humphries SE, et al. Variation in the lipoprotein lipase gene influences exercise-induced left ventricular growth. J Mol Med (Berl). 2006;84(2):126–31. https://doi.org/10.1007/s00109-005-0002-8

19. Kaimoto S, Hoshino A, Ariyoshi M, Okawa Y, Tateishi S, Ono K, et al. Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure. Am J Physiol Heart Circ Physiol. 2017;312(2):H305–H313. https://doi.org/10.1152/ajpheart.00553.2016

20. Dong Z, Zhao P, Xu M, Zhang C, Guo W, Chen H, et al. Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation. Sci Rep. 2017;7(1):2691. https://doi.org/10.1038/s41598-017-02360-5

21. Wei H, Yin M, Chang J, Feng B, Zhou Q, Li X, et al. Empagliflozin's cardioenergetic protective effects through PPARα pathway modulation in heart failure. Front Pharmacol. 2025;16:1636810. https://doi.org/10.3389/fphar.2025.1636810

22. Handford C, Stirling-Barros L, Ganji-Arjenaki M, Mahmod M, Nazarzadeh M, Wamil M. Targeting cardiac metabolism in heart failure with PPARα agonists: A review of preclinical and clinical evidence. Biomedicines. 2025;13(9):2080. https://doi.org/10.3390/biomedicines13092080

23. Park J, Song H, Moon S, Kim Y, Cho S, Han K, et al. Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes. Cardiovasc Diabetol. 2024;23(1):343. https://doi.org/10.1186/s12933-024-02417-6

24. Dhyani N, Saidullah B, Fahim M, Omanwar S. Fenofibrate ameliorates neural, mechanical, chemical, and electrical alterations in the murine model of heart failure. Hum Exp Toxicol. 2019;38(10):1183–94. https://doi.org/10.1177/0960327119860173

25. Pitt B, Vaidya A. Mineralocorticoid receptor antagonist use in hypertension to prevent heart failure. JACC Heart Fail. 2025;13(12):102452. https://doi.org/10.1016/j.jchf.2025.02.021

26. Thuzar M, Stowasser M. The mineralocorticoid receptor-an emerging player in metabolic syndrome? J Hum Hypertens. 2021;35(2):117–23. https://doi.org/10.1038/s41371-020-00467-3

27. Lebrasseur NK, Duhaney TA, De Silva DS, Cui L, Ip PC, Joseph L, Sam F. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension. 2007;50(3):489–96. https://doi.org/10.1161/HYPERTENSIONAHA.107.092403

28. Huang WP, Yin WH, Chen JS, Huang PH, Chen JW, Lin SJ. Fenofibrate reverses dysfunction of EPCs caused by chronic heart failure. J Cardiovasc Transl Res. 2020;13(2):158–70. https://doi.org/10.1007/s12265-019-09889-y

29. Huang WP, Yin WH, Chen JS, Huang PH, Chen JW, Lin SJ. Fenofibrate attenuates doxorubicin-induced cardiac dysfunction in mice via activating the eNOS/EPC pathway. Sci Rep. 2021;11(1):1159. https://doi.org/10.1038/s41598-021-80984-4.